Sidley represented Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, in its US$500 million underwritten public offering of 4,950,496 shares of its Class A common stock at a price to the public of US$101.00 per share. The offering priced on November 18, 2025 and closed on November 20, 2025. J.P. Morgan, Jefferies, TD Cowen, and Cantor are serving as joint book-running managers for the offering.
The selling stockholders – Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund IV, L.P. – have granted the underwriters a 30-day option to purchase up to an additional 742,574 shares at the public offering price.
The Sidley team was led by Rosemary Reilly and Craig Hilts (Emerging Companies and Venture Capital) and included Torrey Cope and Kevin Sforza (Food, Drug and Medical Device); Tanner Groce (Energy and Infrastructure); Emily Ivers (Emerging Companies and Venture Capital); and Talbott Paulsen (M&A).
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
